Total trials
515
Active
82
Phase 3
11
Total enrollment
1,095,117
Pipeline matrix
Showing 40 of 51 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ramipril | — | — | — | — | — | 1 | |
| rituximab | — | — | — | 9 | |||
| methotrexate | — | — | — | — | — | 2 | |
| Leflunomide | — | — | — | — | — | 2 | |
| Abatacept | — | — | — | — | — | 1 | |
| Adalimumab | — | — | — | — | — | 1 | |
| Azathioprine | — | — | — | — | — | 1 | |
| Baricitinib | — | — | — | — | — | 1 | |
| Certolizumab | — | — | — | — | — | 1 | |
| Etanercept | — | — | — | — | — | 1 | |
| Golimumab | — | — | — | — | — | 1 | |
| Hydroxychloroquine | — | — | — | — | — | 1 | |
| Infliximab | — | — | — | — | — | 1 | |
| Minocycline | — | — | — | — | — | 1 | |
| Sarilumab | — | — | — | — | — | 1 | |
| Sulfasalazine | — | — | — | — | — | 1 | |
| Tofacitinib | — | — | — | — | — | 1 | |
| BMX-001 | — | — | — | — | — | 2 | |
| mycophenolate mofetil | — | — | — | — | 6 | ||
| Escitalopram | — | — | — | — | 2 | ||
| sirolimus | — | — | — | — | 2 | ||
| prednisone | — | — | — | 6 | |||
| fluorouracil | — | — | — | — | 6 | ||
| capecitabine | — | — | — | — | 5 | ||
| Oxytocin intranasal spray 24 International Unit | — | — | — | — | — | 2 | |
| Palbociclib 125mg | — | — | — | — | — | 1 | |
| Coenzyme Q10 Cap/Tab | — | — | — | — | — | 1 | |
| Vitamin E Cap/Tab | — | — | — | — | — | 1 | |
| Carmustine 7.7Mg Wafer | — | — | — | — | — | 1 | |
| Androgen Deprivation Therapy | — | — | — | — | — | 1 | |
| Abiraterone | — | — | — | — | — | 1 | |
| isotretinoin | — | — | — | — | — | 1 | |
| Human chorionic gonadotrophin | — | — | — | — | — | 1 | |
| saline placebo | — | — | — | — | — | 1 | |
| Dexamethasone | — | — | — | — | — | 1 | |
| Cannabidiol Administered as Nantheia ATL5 | — | — | — | — | — | 1 | |
| Trabedersen | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| Attenuated-dose Cyclophosphamide | — | — | — | — | — | 1 | |
| High-dose Cyclophosphamide | — | — | — | — | — | 1 |
11 more active programs hidden
Next readouts
- 2025-01-20
- 2026-01-02
- 2026-05
- 2026-06
- 2026-09
- 2026-10
- 2026-12
- 2027-05
- 2027-05
- 2027-06
Top conditions
- Lymphoma21
- Breast Cancer14
- Peripheral Arterial Disease10
- Prostate Cancer8
- Rheumatoid Arthritis8
- Obesity8
- Leukemia8
- Multiple Myeloma8
Frequently asked questions about University of Nebraska
- How many clinical trials does University of Nebraska have on ClinicalTrials.gov?
- University of Nebraska is listed as the lead sponsor on 515 clinical trials in ClinicalTrials.gov, 82 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Nebraska's trials are in Phase 3?
- 11 of University of Nebraska's trials are in Phase 3, spread across 51 active drug programs.
- What therapeutic areas does University of Nebraska focus on?
- University of Nebraska's most-studied conditions on ClinicalTrials.gov are Lymphoma, Breast Cancer, Peripheral Arterial Disease, Prostate Cancer, Rheumatoid Arthritis.
- When are University of Nebraska's next clinical trial readouts?
- University of Nebraska has 10 upcoming primary-completion readouts tracked here; the soonest is “Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma”, expected around 2025-01-20.